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1074Introduction: Patients with chronic distal aortic dissection (CDAD) remain at high risk for late aorta-related
events and reinterventions, and the ideal management strategy remains undefined. Open surgical procedures
carry morbidity, but scant data for thoracic endovascular aortic repair (TEVAR) of CDAD exist. This study re-
ports our intermediate-term results with TEVAR for complicated CDAD.
Methods: All cases of TEVAR for complicated (aortic growth, malperfusion, intractable pain) CDAD at our
institution between 2000 and 2007 were retrospectively reviewed. Demographic information, indications for re-
pair, complications, and aortic morphologic changes were collected from medical records and imaging studies.
Aortic morphology (aneurysm size, false lumen thrombosis) was assessed at multiple levels with 3-dimensional
image analysis techniques. Kaplan-Meier analysis was used to estimate survival, freedom from reintervention,
and likelihood of false lumen thrombosis, with log-rank tests used to discriminate between Kaplan-Meier
curves.
Results: In total, 144 stent–grafts were implanted in 76 consecutive patients (49 male) with complicated CDAD.
Early (<30 postoperative days) mortality was 5%. There was no paraplegia, and 1 patient died of stroke. At
mean follow-up of 34 months, 12 patients had died (1 aorta-related death). Seventeen patients (22%) underwent
19 secondary aortic reinterventions, mainly for enlargement of the untreated aorta remote to stent–graft repair.
Three secondary procedures treated retrograde proximal dissections. Estimated survivals were 86%, 82%, and
80% at 12, 24, and 36 months, respectively, and freedoms from both death and reintervention were 72%, 64%,
and 59% at similar time points. Of 67 patients (88%) with complete imaging follow-up, TEVAR resulted in
significantly decreased aortic diameter through the stent–grafted segment but not untreated segments. Complete
thrombosis of the entire false lumen was uncommon in patients with extensive dissections (13% vs 78%
P<.001).
Conclusions: Management of complicated CDAD remains challenging for clinicians. TEVAR is a reasonable
treatment modality for dissections limited to the thoracic aorta and for prevention of focal aortic growth in ex-
tensive dissections. Late complications and the need for secondary interventions emphasize the complexity of
this patient population and the need for long-term follow-up. (J Thorac Cardiovasc Surg 2011;142:1074-83)Most patients that survive the acute phase of proximal or dis-
tal aortic dissection have a patent false lumen and thus have
persistent disease of the aortic wall. Studies suggest that
75% to 97% of patients survive acute dissections now,mak-
ing chronic distal aortic dissection (CDAD) a relatively
common and concerning issue.1,2 Such patients remain at
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The Journal of Thoracic and Cardiovascular Surrequire subsequent reintervention.3-9 Late complications
in patients with CDAD include aneurysmal growth,
persistent pain, recurrent dissection, end-organ ischemia,
and rupture.
Controversy surrounds the ideal management of patients
with CDAD. Optimal medical therapy with anti-impulse
treatment is used for most patients,8,10 and selected open
surgical or endovascular repair11,12 is used in the setting
of aneurysmal degeneration, malperfusion, persistent pain,
or rupture.8-22 Once intervention is indicated, however,
the best treatment strategies (open vs endovascular) and
the required extent of repair have not been well defined.
Irrespective of the treatment strategy, the goal is to avoid
late aorta-related death. Endovascular repair requires ade-
quate decompression of false lumen perfusion to promote
changes in aortic morphology by closure of the primary inti-
mal entry tear.11-22 The resulting passive decompression of
the false lumen allows true lumen expansion. Although the
results of the treatment of complicated acute aorticgery c November 2011
Abbreviations and Acronyms
CDAD ¼ chronic distal aortic dissection
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Ddissection appear to be favorable for thoracic endovascular
repair (TEVAR), the success of TEVAR during the chronic
phase of an aortic dissection remains controversial.18,20,23
In contrast to acute aortic dissection, the chronically
dissected aorta is characterized by a thick intimal flap with
multiple mature fenestrations,16,18,24 which are thought to
be less amenable to repair than when associated with acute
aortic dissection. Reports on TEVAR for aortic dissection
include mixed groups of patients in both the acute and
chronic phases, with or without complications. The aim of
this study was therefore to report our intermediate-term re-
sults with TEVAR in the specific population of patients
with complicated CDAD.MATERIALS AND METHODS
Patient Population
All patients who underwent a thoracic stent–graft (SG) implantation for
a complicated CDAD from 2000 to 2007 at our institution were retrospec-
tively identified and assessed. CDAD was defined as a dissection involving
the descending thoracic aorta that did not require any interventional or
surgical procedure within the 14 days after the initial diagnosis.25 Compli-
cated CDAD included the following indications: (1) maximum aortic
diameter of at least 55 mm, (2) rapid aortic growth (10mm/y), (3) clinical
or radiographic evidence of rupture, (4) intractable chest pain despite max-
imal medical therapy, and (5) visceral, renal, or lower extremity malperfu-
sion. Patients with penetrating ulcers or intramural hematomas were
excluded from this analysis.
Preoperative Management
Before intervention, a contrast-enhanced computed tomographic scan
of the entire aorta was performed in all cases and supplemented with
angiography, intravascular ultrasonographic analysis, or both as necessary.
Patient selection for TEVAR required a satisfactory proximal landing zone
at least 15 mm in length between the left common carotid artery. The diam-
eter of the proximal landing zone had to be less then 38 mm and either not
dissected or treated previously with an arch or elephant trunk graft repair.
The distal landing zone, in contrast, was typically dissected; however, the
total aortic diameter had to be smaller than 5.5 cm and the true lumen
diameter had to be smaller than 38 mm above the celiac artery.
Endovascular Procedure
All procedures were performed in a hybrid operating room with fixed
imaging, under conditions of general, epidural, or spinal anesthesia. Drain-
age of the cerebrospinal fluid was used in cases of extensive aortic coverage
or previous infrarenal repair. Access was transfemoral except when con-
duits were required as a result of small or calcified iliac arteries. TEVAR
was used to cover the primary intimal tear in the proximal thoracic aorta.
Four types of stent–grafts were used: TX1 and TX2 (Cook Medical Inc,
Bloomington, Ind), TAG (W. L. Gore & Associates, Inc, Flagstaff, Ariz),
Talent (Medtronic, Inc, Minneapolis, Minn), and homemade devices. To
achieve a satisfactory seal, devices were oversized by 10% to 15% with
respect to the diameter of the aorta immediately proximal to the dissection.The Journal of Thoracic and CarBalloon dilatation was performed judiciously to avoid trauma to the
dissected aorta. When no proximal landing zone was available, a hybrid
elephant trunk technique was used, as previously described.26
Postoperative Period and Follow-up
All patients were observed in the intensive care unit after the procedure
for varying lengths of time. In the absence of specific contraindications (re-
nal failure), contrast-enhanced computed tomographic scans of the entire
aorta were performed before discharge, at 6 and 12 months, and yearly
thereafter.
Data Collection
With the approval of our institutional review board, medical records and
radiographic information were reviewed to determine the operative indica-
tions, the repair technique, the perioperative complications, and the later
outcomes. Technical success was defined as a successful proximal entry
tear coverage with TEVAR without conversion to open repair or diagnosis
of type I or III endoleak within the 24 hours after the procedure.
CDADs were classified as limited (with dissection involving the aorta
above the celiac artery level) or extensive (with dissection involving the
aorta below the level of the celiac artery). The aortic morphology (diame-
ter, false lumen patency, and relevant branch vessel status) was examined
with arterial and delayed (5 minute) contrast phases at the following levels:
the proximal thoracic aorta (2 cm below the left subclavian artery ostium),
the midthoracic aorta (at the level of the left inferior pulmonary vein), the
distal thoracic aorta (2 cm above the diaphragm), the celiac artery, the
superior mesenteric artery, both renal arteries, and the infrarenal aorta.
Adverse clinical events (mortality, respiratory failure, limb ischemia,
need for dialysis, stroke, and paraplegia) occurring during the postopera-
tive period and throughout follow-up were recorded. Causes of death
were determined from clinical reports, discussions with families, death cer-
tificates, and autopsy reports when available. Deaths were categorized as
aorta related (within 30 days of any aortic procedure, suggestion of rupture
or malperfusion), not aorta related, or unknown.
Statistical Analysis
Demographic and periprocedural characteristics are shown as number
with percentage or mean  SD. End points were survival, freedom from
reintervention, freedom from both death and reintervention, and any persis-
tent flow in the false lumen of the dissection. Kaplan-Meier analysis was
used to estimate freedoms from the respective outcomes. The log-rank
test was used to evaluate differences between Kaplan-Meier curves.
We graphically analyzed changes in aortic diameters with time at each
of the 8 aortic measurement points as well as overall maximum aortic di-
ameter. Linear mixed models were used to evaluate the changes in the aor-
tic diameter with time for each of the 9 aortic measurements. These models
provided 2 parameters to describe the behavior of the aortic diameter with
time: an intercept (baseline aortic diameter) and a slope (aortic growth rate
in millimeters per year). The presence of persistent flow in the false lumen
of the dissection at each aortic measurement point was noted. Analysis was
stratified by the extent of the dissection (limited vs extensive dissection).
SAS 9.0 (SAS Institute, Inc, Cary, NC) and S-Plus 7.0 (Insightful Corpora-
tion, Seattle, Wash) statistical software packages were used for all statisti-
cal analyses.
RESULTS
A total of 76 consecutive patients (49 men, 65%) under-
went TEVAR for the treatment of complicated CDAD dur-
ing the study period. Mean age at intervention was 61.5 
12.5 years (range, 34–86 years), and the mean time between
the index dissection and the intervention was 25.0  31.0
months (range, 2.6–33.7 months). Baseline demographicdiovascular Surgery c Volume 142, Number 5 1075
TABLE 1. Clinical data
Baseline clinical characteristics
Total population (no.) 76 (100%)
Male (no.) 49 (64%)
Age at diagnosis (y, mean  SD) 59.8  12.4
Age at intervention (y, mean  SD) 61.5  12.5
Time between diagnosis and intervention
(mo, mean  SD)
25.0  31.0
Comorbidities (no.)
Hypertension 75 (99%)
Smoking 32 (42%)
Hyperlipidemia 26 (34%)
Diabetes mellitus 8 (11%)
Renal insufficiency (>1.5 mg/dL) 14 (18%)
Coronary artery disease 29 (38%)
Peripheral artery disease 7 (9%)
Chronic obstructive pulmonary disease 17 (22%)
Previous stroke 9 (12%)
Marfan syndrome 2 (3%)
Previous aortic surgery (no.)
Ascending aortic repair for type A dissection 17 (22%)
Ascending aorta without arch 11
Ascending aorta and hemiarch 3
Elephant trunk repair 3
Infrarenal aneurysm repair 12 (16%)
TABLE 2. Procedural data
Indication
Aneurysmal degeneration (>55 mm) 47 (62%)
Intractable pain 15 (20%)
Rapid growth (>10 mm/y) 9 (12%)
Lower limb claudication 2 (3%)
Visceral ischemia 2 (3%)
Rupture 1 (1%)
Stent–graft type
Gore TAG* 32 (42%)
Cook Zenithy 27 (35%)
Homemade 10 (13%)
Medtronic Talentz 3 (4%)
Multiple types 4 (5%)
Procedure details
General anesthesia 43 (57%)
Cerebrospinal fluid drainage 46 (63%)
Coverage of the left subclavian artery 29 (39%)
Carotid–subclavian bypass 8 (10%)
All data represent numbers and percentages of patients. *W. L. Gore & Associates,
Inc, Flagstaff, Ariz. yCook Medical Inc, Bloomington, Ind. zMedtronic, Inc, Minne-
apolis, Minn.
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persisted after successful repair of a proximal aortic dissec-
tion. Thirty patients (39%) were considered to have a lim-
ited dissection, and the remainder (61%) had extensive
dissections. Indications for repair were as follows: aneurys-
mal degeneration in 47 cases (62%), intractable pain in 15
(20%), rapid growth in 9 (12%), and other (malperfusion,
rupture) in 5 (7%; Table 2)Procedural Details of Initial Endovascular Repair
Technical success was achieved in 73 cases (96%). Tech-
nical failure occurred in 3 patients, all of whom had residual
proximal type I endoleak (noted on postoperative angiogra-
phy). A total of 144 stent–grafts were implanted. The left
subclavian artery was covered in 29 patients (39%). Details
pertaining to the implantation procedure are highlighted in
Table 2. Clinical follow-up was available for all patients,
and 67 patients (88%) had imaging follow-up available.
Mean clinical and imaging follow-up periods were 33.5 
29.4 months (range, 6.1–51.9 months) and 24.2  26.3
months (range, 3–37.8 months), respectively.Mortality
There were 4 early (<30 postoperative days) deaths
(5%), 2 of which occurred during the initial treatment
hospitalization. One of the in-hospital deaths was that of
a 59-year-old woman who presented with malperfusion
(paraplegia and acute renal failure) at admission 2 months
after the surgical repair of a proximal dissection. She died1076 The Journal of Thoracic and Cardiovascular Surof multiple organ failure on postoperative day 2. The second
in-hospital death was that of a 65-year-old man who died of
a subarachnoid hemorrhage 8 days after the treatment of
a CDAD associated with a 7.5-cm aneurysm. Other deaths
within the 30 days of treatment included those of a patient
who died at 12 postoperative days of an unknown cause
and of a second patient who died on postoperative day 17
of a ruptured retrograde proximal dissection (identified at
autopsy; Figure 1). The latter patient had previously been
treated for her dissection with a segmental open surgical de-
scending thoracic graft. She had marked dilation develop
proximal to that repair and underwent TEVAR, which re-
quired subclavian coverage and carotid stenting to achieve
a seal. At the autopsy, the fenestration into the true lumen
appeared to be related to the lack of apposition of the
stent–graft along the lesser curvature of the arch.
Twelve additional patients died during follow-up. One
patient died 6 years after the procedure of rupture of
a chronic ascending aortic dissection. The ascending dissec-
tion in this patient had been observed for many years
because the patient refused surgery and blood products
for religious reasons. Eight deaths were classified as not
aorta related (3 cardiac, 2 cancers, 3 pulmonary infections).
In the 3 remaining cases, the cause of death could not be
determined, and these deaths are considered unknown in
etiology. According to Kaplan-Meier analysis, survivals
were 86%, 82%, and 80% at 12, 24, and 36months, respec-
tively (Figure 2, A).
Morbidity, Endoleaks, and Secondary Aortic
Interventions
Eight patients(11%) had severe but nonlethal postopera-
tive complications, including respiratory failure (prolongedgery c November 2011
FIGURE 1. Ruptured retrograde proximal dissection (arrows) identified at autopsy.
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cases and lower limb ischemia in 1 case. No paraplegia oc-
curred, and the only stroke was that of the patient who died
on postoperative day 8.FIGURE 2. Product–limit survival estimate curves. A, Overall survival. B, Fre
thrombosis of false lumen in patients with limited (blue) and extensive (pink) d
The Journal of Thoracic and CarNine patients (12%) had an endoleak diagnosed on the
initial postoperative computed tomographic scan (7 with
type I endoleak, 1 with type IV endoleak, and 1 with both
type I and type III endoleaks), including 2 of the patientsedom from reintervention. C, Survival free from intervention. D, Complete
issections.
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TABLE 3. Details of the aortic-related reinterventions after thoracic endovascular aortic repair for complicated DCAD
Secondary reintervention Initial repair
Indication and type Time from TEVAR (d) Initial indication Type of SG
Retrograde type A dissection
Ascending and arch replacement 183 Rapid growth Gore TAG*
Ascending and arch replacement 427 Aneurysm Gore TAG*
Ascending and arch replacement 1098 Aneurysmy Custom-made
Aortic enlargement remote to the SG
Infrarenal SG 30 Aneurysm Cook Zenithz
Infrarenal replacement 31 Aneurysm Gore TAG*
Thoracoabdominal replacement 244 Intractable pain Gore TAG*
Infrarenal replacement 366 Aneurysm Gore TAG*
Infrarenal SG 427 Aneurysm Gore TAG*
Thoracoabdominal replacement 732 Aneurysm Custom-made
Frozen elephant trunk 793 Aneurysm Cook Zenithz
Infrarenal SG 1549 Rapid growthx Medtronic Talentk
Thoracic SG 1555 Malperfusion Gore TAG*
Endoleak
Proximal SG (type Ia) 8 Rapid growth Custom-made
Left subclavian artery embolization (type II) 61 Aneurysm Gore TAG*
Frozen elephant trunk (type Ia) 365 Rapid growthx Medtronic Talentk
Stent–graft and true lumen collapse
SG ballooning 6 Aneurysmy Custom-made
Thoracic SG 92 Aneurysm Custom-made
SG ballooning 123 Aneurysm Gore TAG*
TEVAR, Thoracic endovascular aortic repair; SG, stent–graft. *W. L. Gore &Associates, Inc, Flagstaff, Ariz. ySame patient. zCookMedical Inc, Bloomington, Ind. xSame patient.
kMedtronic, Inc, Minneapolis, Minn.
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noid hemorrhage on postoperative day 8 and unknown eti-
ology on postoperative day 12). During follow-up, 4
endoleaks (3 type I and 1 type IV) resolved spontaneously.
Two patients with a type I endoleak underwent secondary
procedures. Two patients (the patient with both type I and
III endoleak and a patient with a type I endoleak) did not
undergo contrast-enhanced computed tomographic scans
during follow-up because of renal failure; however, noncon-
trast scans demonstrated decreases in the proximal and mid-
thoracic aortic diameters. One additional patient was seen
with a large late type II endoleak originating from the left
subclavian artery. This was treated with coil embolization
2 months after the initial TEVAR.
In total, 19 secondary aorta-related interventions were per-
formed in 17 patients (22%). Indications for and types of
these repairs are detailed in Table 3. Of note, 10 secondary re-
pairswere indicated for enlargement of other aortic segments,
9 of which were distal to the stent–graft because of persistent
growth of the untreated segment. Three patients, in addition
to the death mentioned previously, had retrograde dissection
develop and required ascending aortic replacement. Persis-
tent true lumen compression resulted in 2 patients undergoing
repeat ballooning in the setting of endoprosthesis collapse.
According to Kaplan-Meier analysis, freedom from reinter-
vention rates were 83%, 75%, and 73% at 12, 24, and 36
months, respectively (Figure 2, B), and freedom from both1078 The Journal of Thoracic and Cardiovascular Surdeath and reintervention rates were 72%, 64%, and 59% at
12, 24, and 36 months, respectively (Figure 2, C).
Aortic Diameter and False Lumen Thrombosis
Adecrease in the maximal aortic diameter was noted with
time (mean,3.9 6.0 mm, P<.0001). With respect to the
fixed measurement points, this diminution was noted in the
region of the stent–grafted aorta (proximal and middle tho-
racic aorta1.6  4.8 mm, P ¼ .01, and1.9  7.2 mm,
P¼ .04, respectively) for both limited and extensive dissec-
tions. The abdominal aortic diameters increased signifi-
cantly in patients with extensive aortic dissections (Table
4). Diameter increases (5 mm) in the region of the stented
aorta occurred in 10 cases (15%). This was attributable to
type I endoleaks in 2 cases and to persistent retrograde
flow in the false lumen through distal fenestrations in the 8
other cases. Five of these patients underwent an additional
aortic reintervention (2 frozen elephant trunk procedures,
1 thoracoabdominal replacement, 1 infrarenal replacement,
and 1 stent–graft ballooning, as described previously). Over-
all, complete thrombosis of the entire false lumen occurred
in 26 of 67 patients (39%) but was more frequently noted in
patients with limited dissections than in patients with exten-
sive dissections (78% vs 13%, P<.001; Figure 2,D). False
lumen thrombosis was more frequently observed in the
stent–grafted aorta in the proximal (91%) and the midthora-
cic aorta (84%) than at other levels (Table 5).gery c November 2011
TABLE 4. Arterial diameter changes
All patients (n ¼ 67) Extensive dissection (n ¼ 40) Limited dissection (n ¼ 27)
Location Baseline (mm) Growth (mm/y) Baseline (mm) Growth (mm/y) Baseline (mm) Growth (mm/y)
MAD 52.3  11.2 3.87  6.0* 53.6  10.8 5.24  8.0* 50.3  11.7 2.42  3.7*
PTA 41.2  10.2 1.56  4.8* 42.7  9.8 2.74  5.3* 38.9  10.5 0.04  3.1
MTA 45.0  12.6 1.90  7.2y 45.2  12.4 2.29  8.4 44.6  13.0 0.84  2.8
DTA 36.5  8.5 0.34  3.2 39.3  7.8 0.49  3.4 32.5  7.8 0.30  3.1
CA 33.1  7.7 0.10  3.2 36.5  7.5 0.10  3.9 NA NA
SMA 29.7  6.6 0.40  2.0 32.5  6.4 0.58  2.4 NA NA
LRA 26.7  6.4 0.40  1.3y 29.2  6.3 0.58  2.1y NA NA
RRA 27.4  6.8 0.59  1.9y 30.1  6.7 0.91  2.3y NA NA
AA 25.4  7.0 0.30  1.1y 28.1  7.1 0.40  1.5y NA NA
MAD,Maximum aortic diameter; PTA, proximal thoracic aorta;MTA,midthoracic aorta;DTA, distal thoracic aorta;CA, celiac artery;NA, not available; SMA, superior mesenteric
artery; LRA, left renal artery; RRA, right renal artery; AA, abdominal aorta. *P<.01. yP<.05.
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The management of aortic dissection remains among the
most challenging and controversial issues in vascular and
cardiothoracic surgery. The refinement of treatment para-
digms for acute aortic dissection during the past 50 years
has increased the number of patients surviving to the
chronic phase.1,2 Since the first report of TEVAR for
acute aortic dissection and CDAD,27,28 the technique has
been considered as an alternative to open surgery.
Although early results of TEVAR for CDAD demonstrate
its safety and have shown promise, they have been less
favorable with regard to changing the morphology of the
disease than have reports on the treatment of acute
aortic dissection with TEVAR.13-20 In this study, we
demonstrated that the endovascular treatment of patients
with complicated CDAD is a good option for patients
when the dissection is limited to the thoracic aorta and in
extensive dissections is frequently (85% of the time)
effective at promoting thrombosis of the false lumen and
positive remodeling in the treated segments. Yet, much as
with open surgical repair of CDAD, patients often require
subsequent procedures, and serious complications can
occur.
The main treatment goal for CDAD is to minimize the
risk of aorta-related death. This goal may be promoted by
the false lumen exclusion. This occurred in our series in
85% of the patients within the proximal segments, and anTABLE 5. Complete false lumen thrombosis by region
Complete false lumen
thrombosis %
Proximal thoracic aorta 91
Midthoracic aorta 84
Distal thoracic aorta 55
Celiac artery 49
Superior mesenteric artery 35
Left renal artery 17
Right renal artery 21
Infrarenal aorta 19
The Journal of Thoracic and Caroverall diameter reduction was noted in most patients.
The safety of this technique was confirmed by demonstrat-
ing technical success in 96%, with a relatively low perio-
perative mortality of 5%. Of the 4 early deaths, 1 was
that of a patient presenting in extremis, whereas the others
were likely related to the TEVAR (including the death from
unknown cause on postoperative day 12). These cases, and
the 3 late retrograde type A dissections, attest to the fragility
of the aorta in patients with this chronic disease. Careful as-
sessment revealed that the cause of the 4 retrograde dissec-
tions always related to inadequate stent–graft apposition
along the lesser curvature of the arch. This was not device
specific (as it occurred with 2 TAG grafts, one TX2 graft,
and a homemade device). Although a great deal of discus-
sion has focused on the potential for barbs to create dissec-
tions, particularly in patients already prone to dissection,
this was not observed in this series. We were not able to as-
sess the impact of bare uncovered proximal stents because
they have intentionally not been used in dissection patients.
Inadequate apposition along the lesser curvature is a likely
culprit in other complications (see Table 3) in this series,
such as the patient who had a type I endoleak and eventually
had graft collapse of a TAG device. These issues underscore
the importance of disease-specific or anatomically specific
device designs, coupled with an understanding of the aorta
to stent–graft interface. At least 3 of the major stent–graft
companies have attempted to address this issue with newer
versions of arch-specific thoracic devices. The TX2 Pro-
form (Cook Medical) modification allows deployment of
the proximal stent after the second stent allowing it forcing
it to align with the lesser curve. The cTAG (W. L. Gore) de-
vice has a bent shape that is more conformable to the lesser
curvature. The Valiant device (Medtronic) uses a proximal
uncovered stent intended to encourage alignment of the
sealing stent along the lesser curve as well. Despite these
issues, the overall survival in this group of patients with
complicated CDAD (Figure 2, A) compares favorably
with early and late survivals after open surgical repair for
similar conditions.11,12 Thus it is logical to conclude thatdiovascular Surgery c Volume 142, Number 5 1079
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patients with disease that is limited to the descending aorta,
for those with disease remote from the aortic arch, and for
other patients that are considered to be at high risk when
undergoing conventional surgical repair.
This study does not directly address the treatment of un-
complicated CDAD, but the poor event-free survival at 36
months after treatment (59%) in a population of patients re-
quiring intervention at a mean of 2 years after the initial
event raises the question of whether earlier intervention
would be beneficial in a subset of patients to promote aortic
remodeling. Medical therapy for uncomplicated CDADwas
considered equivalent to endovascular treatment in the only
randomized trial assessing subacute and chronic dissec-
tions.29 That study, however, excluded all patients with
complications resulting from their dissections, essentially
the entire patient population in this study. The 2-year
event-free survival of 74% for medical therapy versus
a 72% event-free survival for patients undergoing TEVAR
was far from statistically significant; P ¼ .91). This
event-free survival among patients with uncomplicated dis-
sections actually compares favorably with the event-free
survival among patients treated for complications resulting
from their chronic distal dissections. The crossover between
groups in the INSTEAD trial is indicative of our inability to
predict who is in most need for an intervention and to deter-
mine the optimal extent or aggressiveness of an aortic
repair.30,31 A more detailed understanding of patients with
dissection is required so that we can tailor treatment
paradigms to best suit the disease and its sequelae with
medical, endovascular, or open surgical therapy.
This process begins with imaging the aorta, and the pre-
cise method of image acquisition and interpretation of
CDADmerits discussion. Most reports of TEVAR for aortic
dissection have focused on false lumen thrombosis and
relied on an analysis of only the arterial contrast phase of
the computed tomographic scan.18-20 It is important to
consider that false lumen flow may persist in a delayed
fashion, much as is seen with endoleaks. It is therefore
likely that most reports overestimate the degree of false
lumen thrombosis unless the analysis includes delayed
phase contrast–enhanced imaging in the study. In this
study, both the arterial and the 5-minute contrast delayed
phases were analyzed. The delayed phase images altered
the patency status of the false lumen in 15% to 20% of
the cases. One must remember that contrast-enhanced com-
puted tomographic studies rely on the bolus tracking tech-
nique to trigger the arterial imaging acquisition. This is
usually set within the true lumen in the mid descending tho-
racic aorta. Thus several factors may affect the amount of
contrast within the false lumen, such as the size and location
of fenestrations, the cardiac output, and the dose and con-
centration of contrast administered. Consequently, a multi-
phase study is required for proper assessment of flow1080 The Journal of Thoracic and Cardiovascular Surwithin the false lumen. Even the absence of contrast in the
delayed phase study does not imply thrombosis, although
it does denote a low-flow state. These issues likely explain
the variability observed in the literature regarding false
lumen thrombosis rates and our observation of a low likeli-
hood of complete false lumen thrombosis (13%) in the
setting of extensive dissection.13-22 Similarly, previously
published studies on morphologic aortic changes reporting
aortic diameters have not routinely used imaging
techniques providing images orthogonal to the centerline
of flow.32 Without sophisticated image analysis methods,
fair comparisons between studies at different follow-up
time points may be fraught with error. Traditional centerline
of flow assessment techniques are difficult in patients with
CDAD, however, because most semiautomated programs
cannot differentiate between lumens and contrast levels.
We found that a standardized method of film evaluation
with manually assisted centerline of flow generation and
multiplanar views ensured the accuracy of image compari-
sons during follow-up.
An important goal of TEVAR for CDAD has been to pro-
mote aortic remodeling by achieving false lumen thrombo-
sis because persistent false lumen patency has been
associated with poor long-term outcomes.33-35 Chronic
dissections, typically characterized by a thickened, less
mobile septum and multiple mature fenestrations between
the true and false lumens, potentially makes the aorta less
susceptible to remodeling than in patients with acute
aortic dissection (Figures 3 and 4).18 In this study, false lu-
men thrombosis and aortic diameter diminution occurred
concurrently but were generally limited to the treated aortic
segments, not the other levels (Table 5). We are unable,
however, to assess whether the untreated segments would
have grown faster, slower, or not at all in the absence of
proximal TEVAR. Complete false lumen thrombosis was
uncommon in this series (13%) when dissections were
extensive. These observations have triggered other device-
specific studies, such as the PETTICOAT Trial being
conducted by Cook Medical. In that trial, patients with dis-
section are being treated proximally with a stent–graft, akin
to the methods described here. Distally, uncovered stents
are placed within the true lumen with the hope of inducing
thrombosis or positive remodeling of the noncovered
stented aorta. Irrespective of the state of the distal false lu-
men, the most common site of aneurysmal degeneration
during the chronic phase of an aortic dissection is in the
proximal and midthoracic aorta, regardless of extent. These
segments are also the most amenable to TEVAR. The failure
of TEVAR to treat this region occurred in only 15% of our
patients and was partially explained by the lack of proper
sealing (type I or III endoleaks), coupled with persistent
false lumen flow in the stented segment. Again, the ability
to predict which patients will have persistent flow or inade-
quate sealing on the basis of preoperative imaging will helpgery c November 2011
FIGURE 3. A 54-year-old woman presented with a true lumen compression 4months after the initial dissection. The preoperative CT scan showed an entry
tear in the mid-descending aorta (arrow, A) with a thick intimal flap. The true lumen was extremely reduced in size (arrows, B) with subsequent renal is-
chemia, as confirmed by preoperative angiography. Of note, the right kidney was perfused by the false lumen (arrows, C). The true lumen enlarged signifi-
cantly immediately after endograft deployment (arrows, D). At 1 year follow-up, the CT scan shows a thrombosis of the false lumen and a satisfactory
expansion of the true lumen (E). The bypass to the kidney remains patent on 3D reconstructions (F).
Kang et al Acquired Cardiovascular Disease
A
C
Dto focus therapies for such patients in the future. In our se-
ries, 17 patients (22%) underwent secondary aortic proce-
dures, more than half of which (9/17) entailed aortic
repairs distal to the TEVAR site. It is likely that similar out-
comes occur after limited open repairs, and thus all patients
with residual vulnerable aorta must undergo serial imaging
for their lifetime. The decision to limit extent of the aortic
repair must be based on a balance of paraplegia risk, inva-
siveness of such a repair, and patient comorbidities.29 With-
out better predictors of long-term outcomes, no definitiveThe Journal of Thoracic and Carrecommendation can be universally applied to all patients
with CDAD.
In this single-center report on TEVAR for CDAD, we
were limited by the retrospective nature of the analysis,
the small number of patients (relative to other aortic popu-
lations), and incomplete follow-up in some cases. The mor-
tality was relatively low for this patient population,
technical success was reasonable, and late aorta-related
death was uncommon, making TEVAR a viable alternative
to open surgery for complicated CDAD. Furthermore, thediovascular Surgery c Volume 142, Number 5 1081
FIGURE 4. Chronic dissection (A) is characterized by a thickened, less
mobile septum andmultiplemature fenestrations between the true and false
lumens, making the aorta less susceptible to remodeling than is seen with
acute aortic dissection (B).
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Dability to halt or reverse aortic growth in the stented segment
in 85% of patients is evidence that TEVAR can protect the
aortic wall from adverse morphologic changes. The lack of
complete distal false lumen thrombosis and persistent
growth of untreated segments implies that an optimal means
of treatment still eludes us. Will the addition of uncovered
stents alter the morphologic changes distal to the grafted
aortic segment, or should repairs be carried to a more distal
level, such as the celiac? Can modified devices that improve
conformation along the lesser curve of the aortic arch lessen
the risk of retrograde dissection? When should fenestrated
of branched devices be used to repair the arch or entire thor-
acoabdominal segment? These questions, in addition to the
persistent desire for understanding the truly long-term dura-
bility of stent–grafts in the setting of aortic dissection, re-
main, and they are the subject of ongoing studies.References
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